Thiamphenicol

Identification

Summary

Thiamphenicol is a semisynthetic derivative of chloramphenicol with a broad spectrum of antibacterial activity.

Generic Name
Thiamphenicol
DrugBank Accession Number
DB08621
Background

Not Available

Type
Small Molecule
Groups
Experimental, Investigational
Structure
Thumb
Weight
Average: 356.222
Monoisotopic: 355.004798699
Chemical Formula
C12H15Cl2NO5S
Synonyms
Not Available

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UDr hemagglutinin structural subunitNot AvailableEscherichia coli
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcenocoumarolThe risk or severity of bleeding can be increased when Thiamphenicol is combined with Acenocoumarol.
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Thiamphenicol.
DicoumarolThe risk or severity of bleeding can be increased when Thiamphenicol is combined with Dicoumarol.
EstetrolThe therapeutic efficacy of Estetrol can be decreased when used in combination with Thiamphenicol.
FluindioneThe risk or severity of bleeding can be increased when Thiamphenicol is combined with Fluindione.
LactuloseThe therapeutic efficacy of Lactulose can be decreased when used in combination with Thiamphenicol.
PhenindioneThe risk or severity of bleeding can be increased when Thiamphenicol is combined with Phenindione.
PhenprocoumonThe risk or severity of bleeding can be increased when Thiamphenicol is combined with Phenprocoumon.
Picosulfuric acidThe therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Thiamphenicol.
Typhoid vaccineThe therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Thiamphenicol.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more

Categories

ATC Codes
J01BA02 — ThiamphenicolJ01BA52 — Thiamphenicol, combinations
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as benzenesulfonyl compounds. These are aromatic compounds containing a benzenesulfonyl group, which consists of a monocyclic benzene moiety that carries a sulfonyl group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzenesulfonyl compounds
Direct Parent
Benzenesulfonyl compounds
Alternative Parents
Sulfones / Secondary carboxylic acid amides / Secondary alcohols / Primary alcohols / Organopnictogen compounds / Organonitrogen compounds / Organochlorides / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
show 2 more
Substituents
Alcohol / Alkyl chloride / Alkyl halide / Aromatic alcohol / Aromatic homomonocyclic compound / Benzenesulfonyl group / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Hydrocarbon derivative
show 14 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
sulfone, monocarboxylic acid amide (CHEBI:32215)
Affected organisms
Not Available

Chemical Identifiers

UNII
FLQ7571NPM
CAS number
15318-45-3
InChI Key
OTVAEFIXJLOWRX-NXEZZACHSA-N
InChI
InChI=1S/C12H15Cl2NO5S/c1-21(19,20)8-4-2-7(3-5-8)10(17)9(6-16)15-12(18)11(13)14/h2-5,9-11,16-17H,6H2,1H3,(H,15,18)/t9-,10-/m1/s1
IUPAC Name
2,2-dichloro-N-[(1R,2R)-1,3-dihydroxy-1-(4-methanesulfonylphenyl)propan-2-yl]acetamide
SMILES
[H][C@](CO)(NC(=O)C(Cl)Cl)[C@]([H])(O)C1=CC=C(C=C1)S(C)(=O)=O

References

Synthesis Reference

Franco Pozzi, Claudia Tortora, Angelo Carenzi, "Pharmaceutical preparation containing thiamphenicol for veterinary use." U.S. Patent US4912138, issued January, 1979.

US4912138
General References
Not Available
KEGG Compound
C12853
PubChem Compound
27200
PubChem Substance
99445092
ChemSpider
25315
BindingDB
58925
RxNav
10463
ChEBI
32215
ChEMBL
CHEMBL1236282
ZINC
ZINC000000538440
PDBe Ligand
TH8
Wikipedia
Thiamphenicol
PDB Entries
2jkj

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Suppository
Granule, for solutionOral
Injection, powder, for solution
Powder, for solution
InjectionIntramuscular; Intravenous
Syrup
CapsuleOral500 MG
Suspension
Suspension; syrup
Tablet
Powder
Injection, powder, lyophilized, for solutionIntramuscular; Intravenous
CapsuleOral
CapsuleOral250 mg
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility2.27 mg/mLALOGPS
logP0.33ALOGPS
logP-0.22ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)7.65ChemAxon
pKa (Strongest Basic)-2.8ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area103.7 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity79.88 m3·mol-1ChemAxon
Polarizability32.29 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.931
Blood Brain Barrier+0.9383
Caco-2 permeable-0.61
P-glycoprotein substrateNon-substrate0.7574
P-glycoprotein inhibitor INon-inhibitor0.9489
P-glycoprotein inhibitor IINon-inhibitor0.9432
Renal organic cation transporterNon-inhibitor0.9236
CYP450 2C9 substrateNon-substrate0.5856
CYP450 2D6 substrateNon-substrate0.8164
CYP450 3A4 substrateNon-substrate0.5896
CYP450 1A2 substrateNon-inhibitor0.9045
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.831
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8529
Ames testNon AMES toxic0.7181
CarcinogenicityNon-carcinogens0.6535
BiodegradationReady biodegradable0.706
Rat acute toxicity2.2718 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9972
hERG inhibition (predictor II)Non-inhibitor0.9289
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0a4i-0649000000-3f7e62d09a29a445c8a6
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0002-2931000000-1f1691e17ae627c7d762

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
Kind
Protein
Organism
Escherichia coli
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Hemagglutinins of uropathogenic E.coli mediate adherence to the upper urinary tract. These adhesins bind to the Dr blood group antigen and also agglutinate human erythrocytes in the presence of D-m...
Gene Name
draA
Uniprot ID
P24093
Uniprot Name
Dr hemagglutinin structural subunit
Molecular Weight
17058.095 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Drug created on September 15, 2010 21:33 / Updated on June 19, 2021 00:27